首页> 美国卫生研究院文献>Journal of Clinical Oncology >Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

【2h】

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

机译：每周硼替佐米联合利妥昔单抗治疗复发或复发及难治性沃尔登斯特罗姆巨球蛋白血症的II期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThis study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory Waldenström macroglobulinemia (WM).

机译：目的这项研究旨在确定每周硼替佐米和利妥昔单抗在复发/难治性沃尔登斯特罗姆巨球蛋白血症（WM）患者中的活性和安全性。

著录项

期刊名称 Journal of Clinical Oncology
作者
Irene M. Ghobrial; Fangxin Hong; Swaminathan Padmanabhan; Ashraf Badros; Meghan Rourke; Renee Leduc; Stacey Chuma; Janet Kunsman; Diane Warren; Brianna Harris; Amy Sam; Kenneth C. Anderson; Paul G. Richardson; Steven P. Treon; Edie Weller; Jeffrey Matous;
展开▼
作者单位

展开▼
年(卷),期 -1(28),8
年度 -1
页码 1422–1428
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. [J] . Ghobrial IM, Hong F, Padmanabhan Journal of Clinical Oncology . 2010 ,第8期

机译：每周一次硼替佐米联合利妥昔单抗治疗复发性或复发性和难治性沃尔登斯特罗姆巨球蛋白血症的II期试验。
2. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia [J] . Irene M. Ghobrial, Wanling Xie, Swaminathan Padmanabhan, AMERICAN JOURNAL OF HEMATOLOGY . 2010 ,第9期

机译：每周硼替佐米联合利妥昔单抗治疗未经治疗的沃尔登斯特罗姆巨球蛋白血症患者的II期临床试验
3. Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenstraom Macroglobulinemia Patients [J] . Benevolo Giulia, Ferrero Simone, Andriani Alessandro, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：BRB（Bendamustine，Rituximab和Bortezomib）的临床和分子结果对Fondazione Italiana Linfomi（Fil）进行复发/难治性Waldenstraom癌症患者的临床和分子结果
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab Cyclophosphamide and Prednisone in Relapsed or Refractory non-Hodgkin Lymphoma [O] . John Gerecitano, Carol Portlock, Paul Hamlin, -1

机译：每周的I期临床试验并每周两次用硼替佐米利妥昔单抗环磷酰胺和强的松在复发或难治性非霍奇金淋巴瘤
7. Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia [O] . Ghobrial, Irene M., Hong, Fangxin, Padmanabhan, Swaminathan, 2010

机译：每周硼替佐米联合利妥昔单抗治疗复发或复发及难治性沃尔登斯特罗姆巨球蛋白血症的II期试验

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

摘要

著录项

相似文献

相关主题

期刊订阅